Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/111839
Full metadata record
DC FieldValueLanguage
dc.creatorRodrigues, JG-
dc.creatorBalmaña, M-
dc.creatorMacedo, JA-
dc.creatorPoças, J-
dc.creatorFernandes, Â-
dc.creatorFreitas-Junior, JCM-
dc.creatorPinho, SS-
dc.creatorGomes, J-
dc.creatorMagalhães, A-
dc.creatorGomes, C-
dc.creatorMereiter, S-
dc.creatorReis, CA-
dc.date.accessioned2018-05-08T16:51:35Z-
dc.date.issued2018-
dc.identifier.issn0008-8749-
dc.identifier.urihttp://hdl.handle.net/10216/111839-
dc.description.abstractTumour metastasis is the main cause of cancer related deaths. Metastasis is an intricate multi-step process that requires the acquisition of several cancer cell features, including the modulation of tumour cell migration, adhesion, invasion, and immune evasion. Changes in the cellular glycosylation are associated with malignant transformation of cancer cells, tumour progression and ultimately, metastasis formation. Glycans have major impact on cellular signalling and on the regulation of tumour cell-cell adhesion and cell-matrix interaction. Glycans drive the interplay between the cancer cells and the tumour microenvironment. In this review, we summarize the roles of glycan alterations in tumour progression, such as acquisition of oncogenic features due to modulation of receptor tyrosine kinases, proteoglycans, cadherins and integrins. We also highlight the importance of key glycan binding proteins such as selectins, siglecs and galectins, which are pivotal in the modulation of immune response. An overview on glycans as cancer biomarkers is also presented.pt_PT
dc.description.sponsorshipThis work was funded by FEDER funds through the Operational Programme for Competitiveness Factors-COMPETE (POCI-01-0145-FEDER-016585; POCI-01-0145-FEDER-007274) and National Funds through the Foundation for Science and Technology (FCT), under the projects: PTDC/BBBEBI/0567/2014 (to CAR); PTDC/DTP-PIC/0560/2014 (to SSP) and UID/BIM/04293/2013; and the project NORTE-01-0145-FEDER-000029, supported by Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). The authors acknowledge the support FCT. Grants were received from FCT, POPH (Programa Operacional Potencial Humano) SFRH/BPD/96510/2013 (CG). This work has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 748880.pt_PT
dc.language.isoengpt_PT
dc.publisherElsevierpt_PT
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147342/PTpt_PT
dc.relation.ispartofseriesCellular immunology, vol. pii: S0008-8749(18)30121-7pt_PT
dc.rightsembargoedAccesspt_PT
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/-
dc.subjectBiomarkerspt_PT
dc.subjectCadherinspt_PT
dc.subjectGalectinspt_PT
dc.subjectGlycosylation in cancerpt_PT
dc.subjectIntegrinspt_PT
dc.subjectMetastasispt_PT
dc.subjectProteoglycanspt_PT
dc.subjectReceptor tyrosine kinasept_PT
dc.subjectSelectinspt_PT
dc.subjectSiglecspt_PT
dc.titleGlycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasispt_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.date.embargo2019-03-20-
dc.contributor.uportoInstituto de Investigação e Inovação em Saúdept_PT
dc.identifier.doi10.1016/j.cellimm.2018.03.007-
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S0008874918301217?via%3Dihub-
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
j.cellimm.2018.03.007.pdf655.22 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons